As a result of clinical trials, the improvement rate is about 63% when taken for a month
The SURMOUNT trial program proved it with hard data, showing tirzepatide weight loss results that exceeded anything achieved by GLP-1-only medications
Ready to find out what fits you
As a triple incretin receptor agonist, it: Activates GLP-1 receptors , reducing appetite, slowing gastric emptying, and improving insulin secretion Activates GIP receptors , enhancing insulin response and potentially supporting fat metabolism Activates glucagon receptors , increasing energy expenditure and hepatic glucose output Whilst glucagon receptor activation increases hepatic glucose output, the net glycaemic effect of retatrutide is mitigated by the concurrent GLP-1 and GIP activity, resulting in overall improvements in glycaemic control in trial participants
For professionals working in regulatory affairs, quality assurance or quality control, this means: - Thinking globally while acting locally understanding how guidelines and regulatory frameworks are evolving worldwide
